Meropenem Sandoz

Meropenem, the active ingredient in Meropenem Sandoz, is a carbapenem antibiotic presented as an injection (powder for solution for infusion) for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, meningitis, and sepsis in hospitalized patients.

GNH USA supplies Meropenem Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections. - Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens. - Complicated urinary tract infections: eradicates resistant Gram‑negative and Gram‑positive organisms. - Nosocomial pneumonia: treats hospital‑acquired lung infections caused by multi‑drug‑resistant bacteria. - Meningitis: achieves therapeutic concentrations in cerebrospinal fluid for bacterial meningitis. - Severe sepsis and septic shock: rapidly reduces bacterial load in systemic infection.

Adverse reactions to Meropenem may vary in frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: mild skin erythema. - Infusion site reactions: erythema or phlebitis at the injection site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: potentially life‑threatening diarrhea. - Stevens‑Johnson syndrome: rare mucocutaneous reaction.

When prescribing Meropenem, clinicians should consider several precautionary measures to minimize risks. - Renal function: adjust dose in patients with impaired kidney function. - History of seizures: use cautiously in individuals with CNS disorders. - Hypersensitivity: avoid in patients with known allergy to β‑lactam antibiotics. - Concomitant valproic acid: monitor for reduced antiepileptic levels. - Pregnancy and lactation: category B, use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may decrease serum valproate concentrations, risking seizure breakthrough. - Carbapenem‑induced reduction of oral contraceptives: may diminish contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Aminoglycosides: increased risk of nephrotoxicity when combined. - Loop diuretics: may enhance ototoxicity risk. - Anticoagulants (warfarin): monitor INR as carbapenems can alter coagulation parameters.